Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Further delay for European Parliament committee vote on inclusion of devices in RoHS Directive

This article was originally published in RAJ Devices

Executive Summary

The vote by the European Parliament’s Committee on the Environment, Public Health and Food Safety (ENVI) to adopt proposals to include medical devices within the scope of the directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment (Directive 2002/95/EC) is now due to take place at the plenary session of parliament in July1.

You may also be interested in...



11 Notified Bodies Under MDR Now As Ireland’s NSAI Is Officially Designated

With just over 100 days to go until the full application of the EU Medical Device Regulation, notified body designations are trickling through. Ireland is the latest to now have a resident EU MDR notified body.

Premarket Innovators And SMEs (Part 2): Running Out Of Time In The EU MDR Race

In this second article of a two-part series, Eithne Lee of ISO Life Sciences global consultancy identifies some of the problems that medtech premarket innovators and SMEs are facing, with the EU MDR application date now less than four months away.

Premarket Innovators And SMEs (Part 1): How Many Will Survive EU MDR?

The EU Medical Device Regulation threatens the viability of many premarket innovators and SMEs in the UK, and across Europe. Eithne Lee, of ISO Life Sciences global consultancy, explains how the new requirements come as a shock for many small companies, how many are ill-prepared and how the cost of compliance relative to turnover may be too high. This is part one of a two-part article.

UsernamePublicRestriction

Register

SC096128

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel